Login / Signup

Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial.

Kazuyuki SuzukiRyujin EndoYasuhiro TakikawaFuminori MoriyasuYutaka AoyagiHisataka MoriwakiShuji TeraiIsao SakaidaYoshiyuki SakaiShuhei NishiguchiToru IshikawaHitoshi TakagiAtsushi NaganumaTakuya GendaTakafumi IchidaKoichi TakaguchiKatsuhiko MiyazawaKiwamu Okita
Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)
The efficacy of rifaximin is sufficient and treatment is well tolerated in Japanese patients with HE and hyperammonemia.
Keyphrases
  • phase iii
  • double blind
  • phase ii
  • placebo controlled
  • open label
  • clinical trial
  • study protocol
  • minimally invasive
  • irritable bowel syndrome
  • early onset
  • cross sectional
  • combination therapy
  • randomized controlled trial